Press Release: CareDx to Report First Quarter 2026 Financial Results on April 28, 2026

Dow Jones
04/15
BRISBANE, Calif.--(BUSINESS WIRE)--April 14, 2026-- 

CareDx, Inc. (Nasdaq: CDNA) -- The Transplant Company$(TM)$, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, April 28, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET.

A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone, register here. Upon registering, a dial-in number and unique PIN will be provided.

About CareDx

CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company's integrated solutions include non--invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics--based information for transplant patients. For more information, please visit www.caredx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260414339796/en/

 
    CONTACT:    Investor Contact 

investor@caredx.com

 
 

(END) Dow Jones Newswires

April 14, 2026 16:59 ET (20:59 GMT)

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10